ARRY shows encouraging Ph3 data in BRAF mutant CRC


Congrats to ARRY on positive data for mutant BRAF colorectal cancer (CRC). This interim data should lead to FDA/EMA approvals in this indication and more revenue for ARRY both short-term, because it is already listed on at least one set of guidelines, and long-term post-approval of the likely sNDA filing. Mostly congrats to mBRAF CRC patients who now have a treatment option with positive phase 3 data.

Stock market reaction of over 15% increase at this time (mid-day) is higher than we expected with ORR data of 26.1% in these interim results much lower than 48% in safety lead-in, and with some similar ORR in earlier phase trials for competitive drug candidates. ORR might increase with more time but unlikely to get to safety lead-in ORR levels. http://bit.ly/ARRYCRCint

#AmpFree #ARRY #CRC

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon